LC
BIOTU

Littlejohn & Co’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Littlejohn & Co’s Portfolio BIOTU Stock Details BIOTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-50,000
Closed -$495K – 249
2021
Q1 		$495K Buy
+50,000
New +$514K 0.13% 78

Other funds holding BIOTU

AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PMAM
Picton Mahoney Asset Management Toronto, Ontario, Canada $13.5B AUM 51.46% 1-Year Est. Return

Littlejohn & Co's BIOTU Position: Q2 2021 in Review

Littlejohn & Co sold out of Biotech Acquisition Company Unit (BIOTU) in Q2 2021, closing a stake of 50,000 shares — an estimated $495K sold.

Littlejohn & Co first reported a position in BIOTU in Q1 2021 and held it in 1 quarter. The position peaked at $495K in Q1 2021. 41 funds tracked by Wall St. Rank hold BIOTU as of Q2 2021.

  • Littlejohn & Co reported no remaining Biotech Acquisition Company Unit position as of Q2 2021 after selling out during the quarter.
  • Littlejohn & Co sold 50,000 Biotech Acquisition Company Unit shares in Q2 2021, an estimated $495K.
  • Littlejohn & Co first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 1 quarter.
  • Littlejohn & Co's Biotech Acquisition Company Unit position peaked at $495K in Q1 2021.
  • 41 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q2 2021.

Based on Littlejohn & Co's 13F filing for Q2 2021, filed 12 Aug 2021.